Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-22
2008-03-18
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266220, C514S266300, C514S267000, C544S249000, C544S250000, C544S285000
Reexamination Certificate
active
07345049
ABSTRACT:
Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to α4 integrin. They are used as therapeutic agents for various diseases concerning α4 integrin.
REFERENCES:
patent: 5274098 (1993-12-01), Stueber et al.
patent: 6171578 (2001-01-01), Dean et al.
patent: 6172072 (2001-01-01), Lubisch et al.
patent: 6436925 (2002-08-01), Lubisch et al.
patent: 6436949 (2002-08-01), Lubisch et al.
patent: 6448254 (2002-09-01), Lubisch et al.
patent: 6610710 (2003-08-01), Tanaka et al.
patent: 6855706 (2005-02-01), Tanaka et al.
patent: 7105520 (2006-09-01), Suzuki et al.
patent: 7153963 (2006-12-01), Makino et al.
patent: 2003/0220268 (2003-11-01), Makino et al.
patent: 2003/0220318 (2003-11-01), Suzuki et al.
patent: 2004/0235848 (2004-11-01), Okuzumi et al.
patent: 2005/0101779 (2005-05-01), Sagi et al.
patent: 2005/0107357 (2005-05-01), Scarborough et al.
patent: 2006/0009476 (2006-01-01), Kataoka et al.
patent: 1067431 (1992-12-01), None
patent: 2 354 440 (2001-03-01), None
patent: P0000914 (2001-04-01), None
patent: 2001-89368 (2001-04-01), None
patent: WO 98/38173 (1998-09-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/35163 (1999-07-01), None
patent: WO 99/36393 (1999-07-01), None
patent: WO 99/37618 (1999-07-01), None
patent: WO 99/43642 (1999-09-01), None
patent: WO 01/36376 (2001-05-01), None
patent: WO 01/42215 (2001-06-01), None
patent: WO 01/42225 (2001-06-01), None
patent: WO 01/47868 (2001-07-01), None
patent: WO 01/70670 (2001-09-01), None
patent: WO 02/02556 (2002-01-01), None
patent: WO 02/16329 (2002-02-01), None
patent: WO 02/18320 (2002-03-01), None
patent: WO 02/28830 (2002-04-01), None
patent: WO 03/070709 (2003-08-01), None
patent: WO 2004/074264 (2004-09-01), None
Angela Zeidler et al, “Therapeutic Effects of Antibodies Against Adhesion Molecules in Murine Collagen Type II-Induced Arthritis”,Autoimmunity, 1995, vol. 21, pp. 245-252.
Daniel K. Podolsky et al, “Attenuation of Colitis in the Cotton-top Tamarin by Anti-α4 integrin Monoclonal Antibody”,J. Clin. Invest., Jul. 1993, vol. 92, pp. 372-380.
Tsutomu Takeuchi et al, “Upregulated Expression and Function of Integrin Adhesive Receptors in Systemic Lupus Erythematosus Patients with Vasculitis”,J. Clin. Invest., Dec. 1993, vol. 93, pp. 3008-3016.
S. M. Wellicome et al, “Detection of a circulating form of vascular cell adhesion molecule-1:raised levels in rheumatoid arthritis and systemic lupus erythematosus”,Clin. Exp. Immunol., 1993, vol. 92, pp. 412-418.
Ted A. Yednock et al, “Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin”,Nature, Mar. 5, 1992, vol. 356, pp. 63-66.
Jody L. Baron et al, “Surface Expression of α4 Integrin by CD4 T Cells Is Required for Their Entry into Brain Parenchyma”,J. Exp. Med., Jan. 1993, vol. 177, pp. 57-68.
Ichiro Saito et al, “Expression of Cell Adhesion Molecules in the Salivary and Lacrimal Glands of Sjogren's Syndrome”,Journal of Clinical Laboratory Analysis, 1993, vol. 7, pp. 180-187.
William M. Abraham et al, “α4-Integrins Mediate Antigen-induced late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep”,J. Clin. Invest., Feb. 1994, vol. 93, pp. 776-787.
Hironori Sagara et al, “A Monoclonal Antibody against Very Late Activation Antigen-4 Inhibits Eosinophil Accumulation and Late Asthmatic Response in a Guinea Pig Model of Asthma”,Int. Arch. Allergy Immunol., 1997, vol. 112, pp. 287-294.
Sumi Onuma, “Immunohistochemical Studies of Infiltrating Cells in Early and Chronic Lesions of Psoriasis”,The Journal of Dermatology, 1994, vol. 21, pp. 223-232.
Toshinori Matsui et al, “Effects of anti-VLA-4 Monoclonal Antibody Treatment in Murine Model of Allergic Rhinitis”,Acta Ololaryngol., 2000, vol. 120, pp. 761-765.
Nobuyuki Ebihara et al, “Anti VLA-4 monoclonal antibody inhibits eosinophil infiltration in allergic conjunctivitis model of guinea pig”,Current Eye Research, 1999, vol. 19, No. 1, pp. 20-25.
Jody L. Baron et al, “The Pathogenesis of Adoptive Murine Autoimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1”,J. Clin. Invest., Apr. 1994, vol. 93, pp. 1700-1708.
Simcha R. Meisel et al, “Increased Expression of Neutrophil and Monocyte Adhesion Molecules LFA-1 and Mac-1 and Their Ligand ICAM-1 and VLA-4 Throughout the Acute Phase of Myocardial Infarction”,JACC, Jan. 1998, vol. 31, No. 1, pp. 120-125.
Peggy T. Shih et al, “Blocking Very Late Antigen-4 Integrin Decreases Leukocyte Entry and Fatty Streak Formation in Mice Fed an Atherogenic Diet”,Circ. Res., Feb. 19, 1999, vol. 84, pp. 345-351.
Alan B. Lumsden et al, “Anti-VLA-4 antibody reduces intimal hyperplasia in the endarterectomized cartoid artery in nonhuman primates”,Journal of Vascular Surgery, Jul. 1997, vol. 26, No. 1, pp. 87-93.
Yoshihisa Mori et al, “Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis”,Blood, Oct. 1, 2004, vol. 104, No. 7, pp. 2149-2154.
Hitoshi Okahara et al, “Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1 (VCAM-1) in Tumor Necrosis Factor α Enhancement of Experimental Metastasis”,Cancer Research, Jun. 15, 1994, vol. 54, pp. 3233-3236.
Mitsuaki Isobe et al, “Immunosuppression to Cardiac Allografts and Soluble Antigens by Anti-Vascular Cellular Adhesion Molecule-1 and Anti-Very Late Antigen-4 Monoclonal Antibodies”,The Journal of Immunology, 1994, vol. 153, pp. 5810-5818.
Yoji Shimizu et al, “Integrins in the Immune System”,Advances in Immunology, 1999, vol. 72, pp. 325-380.
Andou Ayatoshi
Fujita Koichi
Ito Hajime
Kageyama Shunsuke
Kataoka Noriyasu
Ajinomoto Co. Inc.
Truong Tamthom N
Wilson James O.
LandOfFree
Phenylalanine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylalanine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylalanine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3967900